Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 10/20 | 0.45 |
| ▸ | ITGAV | P06756 | 10/20 | 0.45 |
| ▸ | ITGA2B | P08514 | 8/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.35 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7479025 | 0.93 | ITGB3 (0.39) | ITGB3ITGAVITGA2BMEN1KMT2A | |
| SCHEMBL7159632 | 0.88 | ITGB3 (0.40) | ITGB3ITGAVITGA2BITGB1 | |
| SCHEMBL7168844 | 0.87 | ITGAV (0.45) | ITGB3ITGAVSMN1; SMN2HSD17B10ITGB1 | |
| SCHEMBL8321280 | 0.86 | ITGB3 (0.37) | ITGB3ITGAVITGA2BMEN1KMT2A | |
| SCHEMBL8319824 | 0.85 | ITGAV (0.40) | ITGB3ITGAVITGA2BTSHRMAPT | |
| SCHEMBL7165010 | 0.85 | ITGB3 (0.41) | ITGB3ITGAVITGA2BTSHRHSD17B10 | |
| SCHEMBL7163713 | 0.85 | ITGB3 (0.40) | ITGB3ITGAVITGA2BMEN1KMT2A | |
| SCHEMBL7368163 | 0.84 | BACE1 (0.39) | ITGB3ITGAVITGA2BTSHRMAPT | |
| SCHEMBL7159817 | 0.84 | ITGB3 (0.45) | ITGB3ITGAVITGA2BITGB1 | |
| SCHEMBL7167733 | 0.83 | TSHR (0.49) | MEN1KMT2ATSHRTP53POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6559144-B2 | Integrin inhibitors used to treat circulatory disorders, for thrombosis, myocardial infarct, coronary heart disease, arteriosclerosis, osteoporosis, pathological processes maintained or propagated by angiogenesis and tumor therapy | MERCK PATENT GESELLSCHAFT MIT (DE) | 2003-05-06 | — | — | US | disclosed |
| EP-0964856-B1 | BICYCLIC AMINO ACIDS | MERCK PATENT GMBH (DE) | 2002-10-09 | — | — | EP | disclosed |
| US-20010021709-A1 | Bicyclic amino acids | MERCK PATENT GESELLSCHAFT MIT BESCHRANKT PATENTS (DE) | 2001-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010021709-A1 | Bicyclic amino acids | ITGA1, ITGB1, ITGB2 | ITGB3 5/4885ITGAV 15/4885ITGA2B 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.